With $34.9M in cash and securities, DiaMedica (DMAC) will likely seek funding within 12 months.

DiaMedica Therapeutics Inc. (DMAC) reported a net loss of $31.5 million for the nine months ended September 30, 2026, with cash and marketable securities totaling $34.9 million and operating cash use at $26.0 million. The company noted substantial doubt about its ability to continue as a going concern, anticipating the need for additional funding within the next 12 months. Despite challenges like slower enrollment in its ReMEDy2 stroke trial, interim results are expected by Q1 2027, and positive pharmacodynamic activity was observed in its preeclampsia study.